CTMX · CytomX Therapeutics, Inc.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-08-03 | Carvajal Alejandra |
Chief Legal Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date. Includes 100,000 RSUs. |
Common Stock
|
100,000 |
| 2026-08-03 | Carvajal Alejandra |
Chief Legal Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-08-03 | Carvajal Alejandra |
Chief Legal Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
450,000 |
| 2026-07-24 | Fuchs Charles S. |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2026-07-24 | Fuchs Charles S. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/36th of the shares subject to the option vest on each monthly anniversary measured from July 24, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
118,000 |
| 2026-06-17 | Meyers James R |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Stock Option (Right to Buy)
|
59,000 |
| 2026-06-17 | Mohindru Mani |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Stock Option (Right to Buy)
|
59,000 |
| 2026-06-17 | Young Matthew P. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Stock Option (Right to Buy)
|
59,000 |
| 2026-06-17 | Ashworth Alan |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Stock Option (Right to Buy)
|
59,000 |
| 2026-06-17 | Jones Elaine V |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Stock Option (Right to Buy)
|
59,000 |
| 2026-06-17 | Gilbert Halley E |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Stock Option (Right to Buy)
|
59,000 |
| 2026-06-17 | Su Zhen |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Stock Option (Right to Buy)
|
59,000 |
| 2026-06-15 | Ogden Christopher |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Includes 167,249 RSUs. |
Common Stock
|
1,624 |
| 2026-03-17 | Ogden Christopher |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Includes 173,082 RSUs. |
Common Stock
|
19,323 |
| 2026-03-17 | McCarthy Sean A. |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Includes 457,500 RSUs. |
Common Stock
|
118,969 |
| 2026-03-17 | BELVIN MARCIA |
SVP, Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Includes 135,833 RSUs. |
Common Stock
|
31,492 |
| 2026-03-17 | Chu Yu-Waye |
Chief Medical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Includes 149,833 RSUs. |
Common Stock
|
21,279 |
| 2026-02-02 | Chu Yu-Waye |
Chief Medical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 206,000 RSUs. |
Common Stock
|
75,000 |
| 2026-02-02 | Lester Rachael |
Chief Business Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 20,000 RSUs. |
Common Stock
|
20,000 |
| 2026-02-02 | Ogden Christopher |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
325,000 |
| 2026-02-02 | McCarthy Sean A. |
Director, CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
980,000 |
| 2026-02-02 | Lester Rachael |
Chief Business Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
50,000 |
| 2026-02-02 | McCarthy Sean A. |
Director, CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 698,750 RSUs. |
Common Stock
|
210,000 |
| 2026-02-02 | Ogden Christopher |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 239,987 RSUs. |
Common Stock
|
90,000 |
| 2026-02-02 | BELVIN MARCIA |
SVP, Chief Scientific Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date. Includes 218,958 RSUs. |
Common Stock
|
60,000 |
| 2026-02-02 | Chu Yu-Waye |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
300,000 |
| 2026-02-02 | Lester Rachael |
Chief Business Officer |
Award↑
Filing footnotes — Performance Stock Units (PSUs) (Direct)
Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. |
Performance Stock Units (PSUs)
|
50,000 |
| 2026-02-02 | BELVIN MARCIA |
SVP, Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
250,000 |
| 2025-11-06 | McCarthy Sean A. |
Director, CEO |
Sell↓
Filing footnotes — Class A Common Stock (Direct)
The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 27, 2024. This transaction was executed in multiple trades at prices ranging from $4.50 to $4.62, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 488,750 restricted stock units. |
Class A Common Stock
|
101,793 |
| 2025-10-20 | Lester Rachael |
Chief Business Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
25% of the shares subject to the option vest on the one year anniversary measured from October 20, 2025 (the "Vesting Commencement Date"), and 1/48th of the shares will vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
650,000 |
| 2025-10-20 | Lester Rachael |
Chief Business Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-09-26 | BELVIN MARCIA |
SVP, Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
36,300 |
| 2025-09-26 | Ogden Christopher |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
78,250 |
| 2025-09-26 | BELVIN MARCIA |
SVP, Chief Scientific Officer |
Award↑
Filing footnotes — Performance Stock Units (PSUs) (Direct)
Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. |
Performance Stock Units (PSUs)
|
18,150 |
| 2025-09-26 | McCarthy Sean A. |
Director, CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
570,000 |
| 2025-09-26 | Chu Yu-Waye |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. |
Stock Option (Right to Buy)
|
87,500 |
| 2025-09-26 | Chu Yu-Waye |
Chief Medical Officer |
Award↑
Filing footnotes — Performance Stock Units (PSUs) (Direct)
Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. |
Performance Stock Units (PSUs)
|
43,750 |
| 2025-09-26 | McCarthy Sean A. |
Director, CEO |
Award↑
Filing footnotes — Performance Stock Units (PSUs) (Direct)
Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. |
Performance Stock Units (PSUs)
|
285,000 |
| 2025-09-26 | Ogden Christopher |
Chief Financial Officer |
Award↑
Filing footnotes — Performance Stock Units (PSUs) (Direct)
Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date. |
Performance Stock Units (PSUs)
|
39,150 |
| 2025-06-16 | BELVIN MARCIA |
SVP, Chief Scientific Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs. Includes 158,958 restricted stock units. |
Common Stock
|
13,884 |
| 2025-06-16 | Ogden Christopher |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs. Includes 149,987 RSUs. |
Common Stock
|
10,614 |
| 2025-06-16 | McCarthy Sean A. |
Director, CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs. Includes 488,750 restricted stock units. |
Common Stock
|
55,511 |
| 2025-06-13 | Ogden Christopher |
Chief Financial Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023. Includes 149,987 RSUs. |
Common Stock
|
37,500 |
| 2025-06-13 | McCarthy Sean A. |
Director, CEO |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023. Includes 488,750 restricted stock units. |
Common Stock
|
150,000 |
| 2025-06-13 | Ogden Christopher |
Chief Financial Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs"). Includes 149,987 RSUs. |
Common Stock
|
1,641 |
| 2025-06-13 | McCarthy Sean A. |
Director, CEO |
Convert↓
Filing footnotes — Performance Stock Units (Direct)
Each PSU represented a contingent right to receive one (1) share of common stock upon vesting. |
Performance Stock Units
|
150,000 |
| 2025-06-13 | BELVIN MARCIA |
SVP, Chief Scientific Officer |
Convert↑
Filing footnotes — Common Stock (Direct)
This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023. Includes 158,958 restricted stock units. |
Common Stock
|
37,500 |
| 2025-06-13 | BELVIN MARCIA |
SVP, Chief Scientific Officer |
Convert↓
Filing footnotes — Performance Stock Units (Direct)
Each PSU represented a contingent right to receive one (1) share of common stock upon vesting. |
Performance Stock Units
|
37,500 |
| 2025-06-13 | Ogden Christopher |
Chief Financial Officer |
Convert↓
Filing footnotes — Performance Stock Units (Direct)
Each PSU represented a contingent right to receive one (1) share of common stock upon vesting. |
Performance Stock Units
|
37,500 |
| 2025-06-11 | Su Zhen |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Stock Option (Right to Buy)
|
38,000 |